logo

Lexicon Pharmaceuticals Inc. (LXRX)



Trade LXRX now with
  Date
  Headline
4/16/2018 7:40:49 AM Wedbush Is Cutting Lexicon Pharmaceuticals Inc. (LXRX) 2018 Estimate To -1.43 From -1.22
4/16/2018 7:40:36 AM Wedbush Is Cutting Lexicon Pharmaceuticals Inc. (LXRX) 4Q18 Estimate To -0.31 From -0.27
4/16/2018 7:40:21 AM Wedbush Is Cutting Lexicon Pharmaceuticals Inc. (LXRX) 3Q18 Estimate To -0.32 From -0.29
4/16/2018 7:40:06 AM Wedbush Is Cutting Lexicon Pharmaceuticals Inc. (LXRX) 2Q18 Estimate To -0.38 From -0.31
4/16/2018 7:39:52 AM Wedbush Is Cutting Lexicon Pharmaceuticals Inc. (LXRX) 1Q18 Estimate To -0.41 From -0.35
4/16/2018 7:39:20 AM Wedbush Is Cutting Lexicon Pharmaceuticals Inc. (LXRX) 2018 Rev. Estimate To 71.1 M From 100.4 M
4/16/2018 7:39:09 AM Wedbush Is Lowering Lexicon Pharmaceuticals Inc. (LXRX) 4Q18 Rev. Estimate To 20.7 M From 31.2 M
4/16/2018 7:38:57 AM Wedbush Is Lowering Lexicon Pharmaceuticals Inc. (LXRX) 3Q18 Rev. Estimate To 17.7 M From 26.7 M
4/16/2018 7:38:47 AM Wedbush Is Lowering Lexicon Pharmaceuticals Inc. (LXRX) 2Q18 Rev. Estimate To 16.8 M From 22.8 M
4/16/2018 7:38:35 AM Wedbush Is Cutting Lexicon Pharmaceuticals Inc. (LXRX) 1Q18 Rev. Estimate To 15.9 M From 19.7 M
3/29/2018 1:00:38 AM Lexicon Reports EMA Acceptance Of MAA For Sotagliflozin To Treat Adults With Type 1 Diabetes
3/26/2018 7:03:48 AM Lexicon Pharma Announces Regulatory Submissions For Sotagliflozin To Treat Adults With Type 1 Diabetes
2/22/2018 7:18:58 AM Lexicon Pharma Q4 Net Loss $28.4 Mln Or $0.27/Shr Vs Loss Of $32.4 Mln Or $0.31/Shr Last Year
12/5/2017 2:12:11 AM Lexicon Secures Up To $200 Mln Non-Dilutive Term Loan Financing
11/30/2017 6:25:54 AM Wedbush Reiterates Lexicon Pharmaceuticals Inc. (LXRX) At Outperform With $38 Price Target
11/30/2017 6:25:11 AM Wedbush Is Increasing Lexicon Pharmaceuticals Inc. (LXRX) 2018 Estimate To -1.01 From -1.24
11/30/2017 6:24:45 AM Wedbush Is Increasing Lexicon Pharmaceuticals Inc. (LXRX) 2017 Estimate To -1.39 From -1.47
11/8/2017 7:13:49 AM Lexicon Q3 Net Loss $30.7 Mln Or $0.29/Shr Vs Net Loss $36.0 Mln Or $0.35/Shr Prior Year
10/5/2017 9:11:21 PM Wedbush Reiterates Lexicon Pharmaceuticals Inc. (LXRX) At Outperform With $38 Down $39 Price Target